Lexicon Pharmaceuticals, Inc. Stock Nasdaq
Equities
US5288721047
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | 25.81M | Sales 2025 * | 77.52M | Capitalization | 399M |
---|---|---|---|---|---|
Net income 2024 * | -186M | Net income 2025 * | -163M | EV / Sales 2024 * | 15.5 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 5.15 x |
P/E ratio 2024 * |
-2.28
x | P/E ratio 2025 * |
-2.56
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.99% |
Latest transcript on Lexicon Pharmaceuticals, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Lonnel Coats
CEO | Chief Executive Officer | 58 | 14-07-06 |
Jeffrey Wade
DFI | Director of Finance/CFO | 59 | 98-12-31 |
Craig Granowitz
CTO | Chief Tech/Sci/R&D Officer | 60 | 21-08-01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Lefkowitz
BRD | Director/Board Member | 80 | 01-01-31 |
Ray Debbane
CHM | Chairman | 69 | 07-07-31 |
Director/Board Member | 65 | 07-08-27 |
1st Jan change | Capi. | |
---|---|---|
-3.71% | 102B | |
+2.26% | 96.84B | |
-0.44% | 21.48B | |
-18.48% | 20.82B | |
-7.45% | 18.6B | |
-40.70% | 16.81B | |
-25.05% | 13.78B | |
+0.51% | 13.4B | |
+22.85% | 11.06B |